NCT07037459ClinicalTrials.gov

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.

التواصل مع هذه الدراسة

باختصار

المرحلة 3مطلوب 5,056 مشاركاً657 موقعاً34 دولة

الفئات

القلب والأوعية الدموية72%الغدد الصمّاء والأيض28%

مسجَّلة في سجل واحد

ClinicalTrials.govNCT07037459فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل 5 أيام

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2025-06-25; recorded start 2025-06-25
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Present: Uses blinding (masking)A masking level is recorded in the record
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 303 other studies in this databaseCounted from the lead sponsor named in the record (Amgen)
Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

The record lists 3 conditions.
Lead sponsor type recorded as: industry.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding13/20
Double-blind
Control arm13/15
Placebo / sham control arm
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
Multi-centre8/8
Multi-centre: 628 sites
Data monitoring committee7/7
A data monitoring committee is in place
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 5,056 participants (target), run at 657 sites, across 34 countries.

How this score is built

Enrolment36/40
5,056 participants (target)
Site count25/25
628 sites
Country count15/15
34 countries
Planned duration10/10
Planned over about 64 months
Sponsor scale9/10
Amgen has led 300 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

الحالات

Heart Failure With Preserved Ejection Fraction
Heart Failure With Mildly Reduced Ejection Fraction
Obesity

الأهلية

الأهلية
الجنس	الجميع
الأعمار	18 Years – 99 Years
المتطوعون الأصحّاء	لا

الأهلية كما كُتبت في السجل

Inclusion Criteria: * Age ≥ 18 years at the time of informed consent. * BMI ≥ 30.0 kg/m\^2 at randomization. * HF diagnosed for at least 30 days with New York Heart Association (NYHA) Class II-IV at the time of informed consent. * Managed with HF standard of care therapies. * Left ventricular ejection fraction (LVEF) of \> 40% within 12 months before randomization. Exclusion Criteria: * History of any of the following within 60 days prior to or during screening: Type I (spontaneous) MI, valvular replacement or repair, coronary revascularization, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke. * HF due to: hypertrophic cardiomyopathy, infiltrative cardiomyopathy, active or chronic myocarditis, constrictive pericarditis, cardiac tamponade, arrhythmogenic right ventricular or left ventricular cardiomyopathy/dysplasia, uncorrected primary valvular heart disease, clinically significant congenital heart disease. * Hospitalized with acute decompensated HF at the time of or during the screening period. * Type 1 diabetes mellitus, or any type of diabetes with the exception of T2DM or history of gestational diabetes. * For participants with a prior diagnosis of T2DM (including those diagnosed during screening): 1. HbA1c \> 10.0% (86 mmol/mol) at screening 2. Uncontrolled diabetes requiring immediate therapy 3. History of diabetic ketoacidosis or hyperosmolar state/coma within 12 months before randomization 4. One or more episodes of severe hypoglycemia within 6 months before randomization and/or history of hypoglycemia unawareness 5. History or presence of either proliferative diabetic retinopathy, or diabetic maculopathy, or severe non-proliferative diabetic retinopathy; or currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema. * SBP ≥ 180 mmHg during the screening period, or on three or more blood pressure-lowering drugs with a SBP \> 160 mmHg during the screening period (including day 1 prior to randomization). * History of chronic pancreatitis or acute pancreatitis in the 180 days before screening or during the screening period. * Any personal lifetime history of, or family history(first-degree relative\[s\]) of medullary thyroid carcinoma or MEN-2. * eGFR \< 20 mL/min/1.73 m\^2 (CKD-EPI creatinine (Cr)-cystatin C equation) or receiving dialysis at screening. * Calcitonin ≥ 50 ng/L (pg/mL) at screening. * Acute or chronic hepatitis. * Any of the following psychiatric history: 1. History of unstable major depressive disorder or other severe psychiatric disorder within 2 years prior to screening or during the screening period 2. Lifetime history of suicide attempt 3. History of non-suicidal self-injury within 5 years prior to screening or during the screening period. * History of any other condition that, in the opinion of the investigator, may preclude the participant from following the protocol and completing the trial. * Use of any glucagon-like peptide 1 receptor agonist (GLP-1 RA), glucose-dependent insulinotropic polypeptide (GIP) agonists or antagonists, or amylin analogs within 90 days prior to or during the screening period or planned use during the conduct of the trial.

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسة	تدخّلية
المرحلة	المرحلة 3
التخصيص	معشّاة
نموذج التدخّل	PARALLEL
الغرض الأساسي	TREATMENT
التعمية	DOUBLE (2)
التجنيد	مطلوب 5,056 مشاركاً

الجهة الراعية والمتعاونون

Amgen الجهة الراعية

الأذرع والتدخلات

Maridebart CafraglutideEXPERIMENTAL
Participants will receive maridebart cafraglutide subcutaneously (SC)
PlaceboPLACEBO_COMPARATOR
Participants will receive placebo SC

التدخلات

دواء Maridebart cafraglutide
Maridebart cafraglutide will be administered SC.
دواء Placebo
Placebo will be administered SC.

مقاييس النتائج

مقياس النتيجة الأولي
Time to First Occurrence of a Composite Endpoint Consisting of: CV Death or HF Events
Heart Failure events include: hospitalization for HF or urgent HF visits.
الإطار الزمني Up to approximately 35 months
مقياس النتيجة الثانوي
Percent Change from Baseline in Non-high-density Lipoprotein Cholesterol (non-HDL-C)
الإطار الزمني Baseline and Week 72
مقياس النتيجة الثانوي
Percent Change from Baseline in Low-density Lipoprotein Cholesterol (LDL-C), HDL-C, Triglycerides (TG), Very Low-density Lipoprotein Cholesterol (VLDL-C)
الإطار الزمني Baseline and Week 72
مقياس النتيجة الثانوي
Total All-cause Hospitalizations (First and Recurrent Time to Event)
الإطار الزمني Up to approximately 35 months
مقياس النتيجة الثانوي
Number of Participants Achieving ≥ 5-point Change in KCCQ-CSS Score from Baseline for Participants with Baseline KCCQ-CSS Score ≤ 80
The KCCQ is a 23-item disease-specific measure for participants with HF, measuring the participant's perception of their health status. The KCCQ-CSS assesses symptoms and physical limitations, ranging from 0 to 100, with higher scores indicating better functioning and quality of life.
الإطار الزمني Baseline and Week 48
مقياس النتيجة الثانوي
Number of Participants Achieving ≥ 10-point Change in KCCQ-CSS Score from Baseline for Participants with Baseline KCCQ-CSS Score ≤ 80
The KCCQ is a 23-item disease-specific measure for participants with HF, measuring the participant's perception of their health status. The KCCQ-CSS assesses symptoms and physical limitations, ranging from 0 to 100, with higher scores indicating better functioning and quality of life.
الإطار الزمني Baseline and Week 48
مقياس النتيجة الثانوي
Number of Participants Achieving an Anchor-based Change in KCCQ-CSS Score From Baseline for Participants with Baseline KCCQ-CSS Score ≤ 80
The KCCQ is a 23-item disease-specific measure for participants with HF, measuring the participant's perception of their health status. The KCCQ-CSS assesses symptoms and physical limitations, ranging from 0 to 100, with higher scores indicating better functioning and quality of life. The Patient Global Impression of Severity (PGI-S) and Patient Global Impression of Change (PGI-C) can be used as anchors to estimate within-patient change in the KCCQ-CSS score.
الإطار الزمني Baseline and Week 48
مقياس النتيجة الثانوي
Number of Participants Achieving ≥ 5-point Change in KCCQ-TSS Score from Baseline for Participants with Baseline KCCQ-CSS Score ≤ 80
The KCCQ is a 23-item disease-specific measure for participants with HF, measuring the participant's perception of their health status. The KCCQ-TSS assesses symptom frequency and burden, ranging from 0 to 100, with higher scores indicating better functioning and quality of life. The KCCQ-CSS assesses symptoms and physical limitations, ranging from 0 to 100, with higher scores indicating better functioning and quality of life.
الإطار الزمني Baseline and Week 48
مقياس النتيجة الثانوي
Change from Baseline in the Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
الإطار الزمني Baseline and Week 72
مقياس النتيجة الثانوي
Change from Baseline in Body Mass Index (BMI) (kg/m^2)
الإطار الزمني Baseline and Week 72
مقياس النتيجة الثانوي
Change from Baseline in the Waist Circumference (cm)
الإطار الزمني Baseline and Week 72
مقياس النتيجة الثانوي
Change from Baseline in the Urine Albumin-to-creatinine Ratio (uACR)
الإطار الزمني Baseline and Week 72
مقياس النتيجة الثانوي
Change from Baseline in the Hemoglobin A1c (HbA1c [%, mmol/mol]) and fasting plasma glucose (mg/dL)
الإطار الزمني Baseline and Week 72
مقياس النتيجة الثانوي
Percent Change from Baseline in the High-sensitivity C Reactive Protein (hs-CRP)
الإطار الزمني Baseline and Week 72
مقياس النتيجة الثانوي
Percent Change from Baseline in the Body Weight (kg)
الإطار الزمني Baseline and Week 72
مقياس النتيجة الثانوي
Percent Change from Baseline in Total Cholesterol
الإطار الزمني Baseline and Week 72
مقياس النتيجة الثانوي
Time to Onset of Type 2 Diabetes Mellitus (T2DM) in Participants with Prediabetes
الإطار الزمني Up to approximately 35 months
مقياس النتيجة الثانوي
Time to the First HF Event
الإطار الزمني Up to approximately 35 months
مقياس النتيجة الثانوي
Time to First Event of a Composite Nephropathy Endpoint
The composite nephropathy endpoint consists of: persistent macroalbuminuria, persistent ≥ 40% reduction in estimated glomerular filtration rate (eGFR), onset of persistent eGFR \< 15 mL/min/1.73 m\^2, initiation of chronic renal replacement therapy (dialysis or transplantation), CV or renal death.
الإطار الزمني Up to approximately 35 months
مقياس النتيجة الثانوي
Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) for Participants with Baseline KCCQ-CSS Score ≤ 80
The KCCQ is a 23-item disease-specific measure for participants with HF, measuring the participant's perception of their health status. The KCCQ-CSS assesses symptoms and physical limitations, ranging from 0 to 100, with higher scores indicating better functioning and quality of life.
الإطار الزمني Baseline and Week 48
مقياس النتيجة الثانوي
Change from Baseline in the KCCQ Total Symptom Score (TSS) for Participants with Baseline KCCQ-CSS Score ≤ 80
The KCCQ is a 23-item disease-specific measure for participants with HF, measuring the participant's perception of their health status. The KCCQ-TSS assesses symptom frequency and burden, ranging from 0 to 100, with higher scores indicating better functioning and quality of life.
الإطار الزمني Baseline and Week 48
مقياس النتيجة الثانوي
Total Number of HF Events Including First and Recurrent HF Events
الإطار الزمني Up to approximately 35 months
مقياس النتيجة الثانوي
Time to First Occurrence of a Composite Endpoint Consisting of: Myocardial Infarction (MI), Ischemic Stroke, CV Death (Major Adverse Cardiac Events [MACE]), or HF Events
الإطار الزمني Up to approximately 35 months
مقياس النتيجة الثانوي
Change in eGFR Slope (Total)
الإطار الزمني Baseline up to approximately 35 months
مقياس النتيجة الثانوي
Change in eGFR Slope (Chronic)
الإطار الزمني From 4 months up to approximately 35 months
مقياس النتيجة الثانوي
Number of Participants Achieving ≥ 10-point Change in KCCQ-TSS Score from Baseline for Participants with Baseline KCCQ-CSS Score ≤ 80
The KCCQ is a 23-item disease-specific measure for participants with HF, measuring the participant's perception of their health status. The KCCQ-TSS assesses symptom frequency and burden, ranging from 0 to 100, with higher scores indicating better functioning and quality of life. The KCCQ-CSS assesses symptoms and physical limitations, ranging from 0 to 100, with higher scores indicating better functioning and quality of life.
الإطار الزمني Baseline and Week 48
مقياس النتيجة الثانوي
Number of Participants Achieving an Anchor-based Change in KCCQ-TSS Score from Baseline for Participants with Baseline KCCQ-CSS Score ≤ 80
The KCCQ is a 23-item disease-specific measure for participants with HF, measuring the participant's perception of their health status. The KCCQ-TSS assesses symptom frequency and burden, ranging from 0 to 100, with higher scores indicating better functioning and quality of life. The KCCQ-CSS assesses symptoms and physical limitations, ranging from 0 to 100, with higher scores indicating better functioning and quality of life. The PGI-S and PGI-C can be used as anchors to estimate within-patient change in the KCCQ-CSS score.
الإطار الزمني Baseline and Week 48
مقياس النتيجة الثانوي
Time to All-cause Death
الإطار الزمني Up to approximately 35 months
مقياس النتيجة الثانوي
Time to CV Death
الإطار الزمني Up to Approximately 35 Months
مقياس النتيجة الثانوي
Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events
الإطار الزمني Up to approximately 35 months
مقياس النتيجة الثانوي
Plasma Concentration of Maridebart Cafraglutide
الإطار الزمني Week 72
مقياس النتيجة الثانوي
Change from Baseline in N-terminal Pro B Type Natriuretic Peptide (NT-proBNP)
الإطار الزمني Baseline and Week 72
مقياس النتيجة الثانوي
Time to New Onset of Atrial Fibrillation (AF) or Atrial Flutter (AFL) in Participants Without a History of AF or AFL at Baseline
الإطار الزمني Baseline and up to approximately 35 months
مقياس النتيجة الثانوي
Time to First Event of a Composite Nephropathy Endpoint
The composite nephropathy endpoint consisting of persistent ≥ 40% reduction in estimated glomerular filtration rate (eGFR), onset of persistent eGFR \< 15 mL/min/1.73 m\^2, initiation of chronic renal replacement therapy (dialysis or transplantation), or CV death.
الإطار الزمني Up to approximately 35 months

التواريخ

التواريخ
تاريخ البدء	25 يونيو 2025 (فعلي)
الإتمام الأولي	30 يونيو 2028 (تقديري)
الإتمام	29 سبتمبر 2030 (تقديري)
أول نشر	25 يونيو 2025 (فعلي)
آخر تحديث	16 سبتمبر 2026
النتائج منشورة	غير مذكور في سجل السجل
آخر تأكيد للحالة	سبتمبر 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

637 موقعاً قيد التجنيد

Argentina

Argentina
المنشأة	المدينة	الولاية أو المنطقة	الحالة
Centro Medico Dra Laura Maffei Investigacion Clinica Aplicada	CABA	Buenos Aires	قيد التجنيد
Centro de Investigaciones Metabolicas Cinme	CABA	Buenos Aires	قيد التجنيد
Imoba Investigaciones medicas	CABA	Buenos Aires	قيد التجنيد
Fundacion Respirar - Consultorios Medicos Dr Doreski	CABA	Buenos Aires	قيد التجنيد
Cemic - Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno	CABA	Buenos Aires	قيد التجنيد
Cemedic Centro de Especialidades Medicas	CABA	Buenos Aires	قيد التجنيد
Cardiología Palermo	Ciudad Autonoma de Buenos Aires	Buenos Aires	قيد التجنيد
Ciprec Centro de Investigacion y Prevencion Cardiovascular	Ciudad Autonoma de Buenos Aires	Buenos Aires	قيد التجنيد
Mautalen Salud e Investigacion Expertia SA-Osteo	Ciudad Autonoma de Buenos Aires	Buenos Aires	قيد التجنيد
Instituto Medico Damic	Córdoba		قيد التجنيد
Ciad - Consultorio Integral de Atencion al Diabetico	Morón	Buenos Aires	قيد التجنيد
Dim Clinica Privada	Ramos Meija	Buenos Aires	قيد التجنيد
Instituto de Investigaciones Clínicas Rosario-Sanatorio Delta	Rosario	Santa Fe Province	قيد التجنيد
INECO Neurociencias Oronio	Rosario		قيد التجنيد
Instituto CAICI - Centro de Asistencia e Investigacion Clinica Integral	Rosario	Santa Fe Province	قيد التجنيد
Centro Modelo de Cardiologia	San Miguel de Tucumán	Tucumán Province	قيد التجنيد
Investigaciones Clinicas Tucuman	San Miguel de Tucumán	Tucumán Province	قيد التجنيد
Instituto de Investigaciones Clinicas de San Nicolas	San Nicolás de los Arroyos	Buenos Aires	قيد التجنيد
Go Centro Medico San Nicolas	San Nicolás de los Arroyos	Buenos Aires	قيد التجنيد
Hospital Dr Jose Maria Cullen	Santa Fe		قيد التجنيد
Centro de Investigaciones Clinicas del Litoral	Santa Fe		قيد التجنيد
Clinica Fusavim Privada SRL	Villa María	Córdoba Province	قيد التجنيد
Instituto de Investigaciones Clinicas Zarate	Zárate		قيد التجنيد

Australia

Australia
المنشأة	المدينة	الولاية أو المنطقة	الحالة
Advara HeartCare Wesley	Auchenflower	Queensland	أُنهي
Flinders Medical Centre	Bedford Park	South Australia	قيد التجنيد
Sunshine Coast University Hospital	Birtinya	Queensland	قيد التجنيد
Victorian Heart Hospital	Clayton	Victoria	قيد التجنيد
Canberra Hospital	Garran	Australian Capital Territory	قيد التجنيد
Royal Brisbane and Womens Hospital	Herston	Queensland	قيد التجنيد
Advara HeartCare Joondalup	Joondalup	Western Australia	قيد التجنيد
Advara HeartCare Leabrook	Leabrook	South Australia	قيد التجنيد
Sydney Cardiometabolic Centre	Liverpool	New South Wales	قيد التجنيد
The Alfred Hospital	Melbourne	Victoria	قيد التجنيد
Core Research Group Pty Ltd	Milton	Queensland	قيد التجنيد
Advara HeartCare Mulgrave	Mulgrave	Victoria	قيد التجنيد
Fiona Stanley Hospital	Murdoch	Western Australia	قيد التجنيد
Gold Coast Hospital and Health Service	Southport	Queensland	أُنهي
Royal North Shore Hospital	St Leonards	New South Wales	قيد التجنيد
Dr Heart Pty Ltd	Woolloongabba	Queensland	أُنهي

Austria

Austria
المنشأة	المدينة	الحالة
Krankenhaus Sankt Josef Braunau	Braunau am Inn	قيد التجنيد
Pro Kompetenzzentrum fuer Gesundheit	Graz	قيد التجنيد
Medizinische Universitaet Graz	Graz	قيد التجنيد
Klinikum Klagenfurt am Woerthersee	Klagenfurt	قيد التجنيد
Ordensklinikum Linz Elisabethinen	Linz	قيد التجنيد
Landeskrankenhaus Salzburg	Salzburg	قيد التجنيد
Imed Sankt Poelten	Sankt Pölten	قيد التجنيد
Universitaetsklinikum Sankt Poelten	Sankt Pölten	أُنهي
Universitaetsklinikum Allgemeines Krankenhaus Wien	Vienna	قيد التجنيد
Herz Zentrum Waehring	Vienna	قيد التجنيد
Ordinationszentrum imedneunzehn privat	Vienna	قيد التجنيد

تُدرَج 607 مواقع إضافية في سجل السجل.

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

16 سبتمبر 2026
أُضيف موقع
29 sites added (657 total)
628657

السجل: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT07037459